Long-Term Efficacy of an Imidacloprid 10 % / Flumethrin 4.5 % Polymer Matrix Collar (Seresto®, Bayer) against the Australian Paralysis Tick (Ixodes holocyclus) in Dogs

Smith, Warwick M.; Ahlstrom, Liisa A.; Rees, Robert

doi:10.1007/s00436-013-3276-8

Cited by 8 publications

(7 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors. (Bos and Curtis, 2002) An efficacy of 0.95 against I. ricinus for deltamethrin 4% was reached over a period of 5.5 months Imidacloprid EC 428-040-8 (Smith et al, 2013) Substance is very toxic to aquatic life, is very toxic to aquatic life with long lasting effects and is harmful if swallowed.…”

Section: Disclaimermentioning

confidence: 99%

“…External usecollar/ear tag A combination of imidacloprid 10% /flumethrin 4.5% reached a maximum efficacy against I. holocyclus of 1 87 post-treatment before decreasing to 0.66 227 days posttreatment (Epe et al, 2003) External usetopic/spray A combination of Imidacloprid 10%/Permethrin 50% had an efficacy of 0.92 37 days post treatment (Hellmann et al, 2003) A combination of Imidacloprid 10%/Permethrin 50% had an efficacy of 0.96 28 days post treatment Flumethrin (Smith et al, 2013) External usecollar/ear tag A combination of imidacloprid 10% /flumethrin 4.5% reached a maximum efficacy against I. holocyclus of 1 87 post-treatment before decreasing to 0.66 227 days posttreatment Metaflumizone EC 604-167-6 (Hellmann et al, 2007) Substance is very toxic to aquatic life, is very toxic to aquatic life with long lasting effects and may cause damage to organs through prolonged or repeated exposure.…”

Section: Disclaimermentioning

confidence: 99%

See 1 more Smart Citation

Data collection for risk assessments on animal health (Acronym: DACRAH) : Final Report

Dórea

Swanenburg²,

Roermund³

et al. 2017

EFSA Supporting Publications

View full text Add to dashboard Cite

Section: Disclaimermentioning

confidence: 99%

Section: Disclaimermentioning

confidence: 99%

Data collection for risk assessments on animal health (Acronym: DACRAH) : Final Report

Dórea

Swanenburg²,

Roermund³

et al. 2017

EFSA Supporting Publications

View full text Add to dashboard Cite

“…Smith et al (2013) demonstrated 4 month efficacy (> 97.9 %) for the Seresto ® collar against the I. holocyclus. However, repellency was not assessed in this study.…”

Section: Dantasmentioning

confidence: 99%

“…It has been shown to achieve long-term persistent efficacy of 8 months against fleas (Ctenocephalides felis felis) (Stanneck et al 2012b(Stanneck et al , 2012c) and 4 months against I. holocyclus on dogs (Smith et al 2013). The Seresto ® collar has also been shown to be highly effective in the prevention of trans mission of VBD from ticks to dogs (Dantas-Torres et al 2013).…”

Section: Introductionmentioning

confidence: 99%

Repellency Effect of an Imidacloprid / Flumethrin (Seresto®) Controlled Release Polymer Matrix Collar against the Australian Paralysis Tick (Ixodes holocyclus) in Dogs

Burgh

Hunter²,

Jackson³

et al. 2017

Parasitol Res

View full text Add to dashboard Cite

Repellency is a highly desirable attribute for an acaricide that protects dogs against the Australian paralysis tick (Ixodes holocyclus). A bite from a single tick of this species can be fatal and carries the risk of transmission of vector-borne diseases. A randomised, controlled study was conducted to confirm the repellency sensu stricto and sensu lato (expellency) of a 10 % imidacloprid/4.5 % flumethrin collar (Seresto ® , Bayer) on dogs, against artificial infestations of I. holocyclus. Based on a novel protocol, dogs treated with Seresto ® , or a placebo collar, were sedated and placed in infestation chambers for 1 h at varying time points up to 6 months after treatment. Ticks were released alongside the dogs, and allowed to approach and/or attach. Treating dogs with a Seresto ® collar resulted in significantly (p < 0.001) more residual ticks being found in the infestation chambers (repellency sensu stricto) compared to the placebo treated dogs for the 168-day duration of the study (range 67.5% to 90.2 %). Repellency sensu lato (expellency) was reflected in significantly (p <0.002) fewer ticks being found attached to treated dogs throughout the study. Comparative decrease in ticks attached exceeded 95 % for 84 days, when assessed after 6 h. When assessed after 24 h, there was a > 95 % comparative decrease in ticks attached until Day 84, > 90 % on Days 112 and 140 then > 95 % to Day 168. Efficacy (killing effect) of the Seresto ® collar based on total live tick counts was > 95 % 6 h after tick challenge throughout the 6 month study period. This study demonstrated the excellent repellency effect of the Seresto ® collar against I. holocyclus in dogs. S146Ectopar asitEs

show abstract

“…The collar also exhibits repellent (anti feeding) efficacy and has the potential to prevent infections with flea and tick transmitted agents Fourie et al 2013a;Fourie et al 2013b;Lappin et al 2013;Otranto et al 2013, Reichard et al 2013Brianti et al 2014). The collar contains two actives, the insecticide imidacloprid active against fleas and lice, and the acaricide flumethrin active against ticks and mites (Stanneck et al 2012b;Stanneck et al 2012c;Brianti et al 2013;Smith et al 2013). The actives themselves have a relatively long history.…”

Section: Introductionmentioning

confidence: 99%

Chemical Compatibility and Safety of Imidacloprid/Flumethrin Collar (Seresto®) Concomitantly Used with Imidacloprid/Moxidectin (Advocate®, Advantage® Multi) and Emodepside/Praziquantel (Profender®) Spot-on Formulations

et al. 2015

View full text Add to dashboard Cite

Safety of concomitant use of veterinary products is of clinical interest. A series of studies was performed to evaluate the chemical compatibility and short term dermal and systemic safety of an imidacloprid/ flumethrin collar (Seresto ® / Foresto ® , Bayer) used concomitantly with spot-on or tablet formulations. Chemical compatibility was evaluated in-vitro (study reference A) on collar pieces, followed by two small, non-controlled clinical studies (study reference B) in both, cats and dogs. The studies showed, that certain solvents affected the collar in-vitro, but not in their marketed formulations.Dermal and systemic safety of different spot-on or tablet formulations was first evaluated in a small, non-controlled clinical study (study reference C) in cats and dogs, via clinical observations only, followed by controlled clinical safety studies of concomitant use with imidacloprid/ moxidectin (Advocate ® / Advantage ® Multi, Bayer) in dogs and cats (study reference D) and emodepside/ praziquantel (Profender ® , Bayer) in cats (study reference E), assessing safety aspects by clinical observations and statistical analyses of hematology and clinical chemistry parameters compared to baseline values and between treated and control groups. S55 Ectopar asitEsDermal safety findings over all clinical studies (study references B to E) matched those already described for the respective products and included transient cosmetic changes (oily hair and crystal formation) at the site of spot-on application and broken hair, transient alopecia and skin alterations at the site of collar application. There were no indications of these findings aggravating under the conditions of concurrent use. There were no systemic safety findings of clinical significance in any of the clinical safety studies (study reference C to E). Assessment of blood parameters revealed some deviations from baseline levels and from the reference range in dogs as well as in cats, but no clinical relevance could be deduced. Hematology and clinical chemistry results confirmed the safety of the concomitant treatment. It is concluded that Seresto ® is chemically compatible with solvents used in major spot-on formulations on the market and is dermally and systemically safe for adult dogs and cats when used concomitantly with Advocate ® and Profender ® spot-on formulations.

show abstract

Long-Term Efficacy of an Imidacloprid 10 % / Flumethrin 4.5 % Polymer Matrix Collar (Seresto®, Bayer) against the Australian Paralysis Tick (Ixodes holocyclus) in Dogs

Cited by 8 publications

References 12 publications

Data collection for risk assessments on animal health (Acronym: DACRAH) : Final Report

Data collection for risk assessments on animal health (Acronym: DACRAH) : Final Report

Repellency Effect of an Imidacloprid / Flumethrin (Seresto®) Controlled Release Polymer Matrix Collar against the Australian Paralysis Tick (Ixodes holocyclus) in Dogs

Chemical Compatibility and Safety of Imidacloprid/Flumethrin Collar (Seresto®) Concomitantly Used with Imidacloprid/Moxidectin (Advocate®, Advantage® Multi) and Emodepside/Praziquantel (Profender®) Spot-on Formulations

Contact Info

Product

Resources

About